Welcome to the latest issue of EMJ Oncology! We are proud to share with you an impressive collection of new and interesting research, alongside our independent review of European Society for Medical Oncology (ESMO) Virtual Congress 2020 with research and breaking news from the virtual event.
Latest articlesAll articles
Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer
Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.
Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.
The Contradictory Phenomena: Development of a New Life and a Life-Threatening Illness: Colorectal Cancer in Pregnancy
Colorectal cancer (CRC) ranks as the third most common type of cancer in women. Patients aged 50 years and above constitute the highest percentage of patients diagnosed with the disease.